Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl (Q34669325)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl |
scientific article |
Statements
1 reference
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl (English)
1 reference
Josep Tabernero
1 reference
Takayuki Yoshino
1 reference
Allen Lee Cohn
1 reference
Radka Obermannova
1 reference
Gyorgy Bodoky
1 reference
Rocio Garcia-Carbonero
1 reference
Tudor-Eliade Ciuleanu
1 reference
David C Portnoy
1 reference
Axel Grothey
1 reference
Jana Prausová
1 reference
Pilar Garcia-Alfonso
1 reference
Kentaro Yamazaki
1 reference
Philip R Clingan
1 reference
Sara Lonardi
1 reference
Tae Won Kim
1 reference
Lorinda Simms
1 reference
Shao-Chun Chang
1 reference
Federico Nasroulah
1 reference
RAISE Study Investigators
1 reference
12 April 2015
1 reference
1 reference
Identifiers
1 reference